253 related articles for article (PubMed ID: 21519841)
21. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
23. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
24. Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.
Chan A; Shannon C; de Boer R; Baron-Hay S; Redfern A; Bauwens A; Craft P; Webb S; Townsend A; Kotasek D
Asia Pac J Clin Oncol; 2014 Dec; 10(4):368-75. PubMed ID: 25351929
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
26. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Thallinger C; Lang I; Kuhar CG; Bartsch R; Singer CF; Petruzelka L; Melichar B; Knittelfelder R; Brodowicz T; Zielinski C
BMC Cancer; 2016 Feb; 16():121. PubMed ID: 26887956
[TBL] [Abstract][Full Text] [Related]
27. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
[TBL] [Abstract][Full Text] [Related]
28. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
[TBL] [Abstract][Full Text] [Related]
29. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
30. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
[TBL] [Abstract][Full Text] [Related]
32. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
33. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.
Coudert B; Focan C; Genet D; Giacchetti S; Cvickovic F; Zambelli A; Fillet G; Chollet P; Amoroso D; Van Der Auwera J; Lentz MA; Marreaud S; Baron B; Gorlia T; Biville F; Lévi F
Chronobiol Int; 2008 Sep; 25(5):680-96. PubMed ID: 18780198
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.
Guerrero A; Servitja S; Rodríguez-Lescure A; Calvo L; del Barco S; Quintanar MT; Juárez JI; Gayo J; Llombart A; Tusquets I
Anticancer Drugs; 2011 Mar; 22(3):283-9. PubMed ID: 21150776
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.
Nguyen L; Tranchand B; Puozzo C; Variol P
Br J Clin Pharmacol; 2002 May; 53(5):459-68. PubMed ID: 11994051
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Chew HK; Somlo G; Mack PC; Gitlitz B; Gandour-Edwards R; Christensen S; Linden H; Solis LJ; Yang X; Davies AM
Ann Oncol; 2012 Apr; 23(4):1023-9. PubMed ID: 21778300
[TBL] [Abstract][Full Text] [Related]
38. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
[TBL] [Abstract][Full Text] [Related]
40. A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).
Fumoleau P; Koch KM; Brain E; Lokiec F; Rezai K; Awada A; Hayward L; Werutsky G; Bogaerts J; Marréaud S; Cardoso F
Breast; 2014 Oct; 23(5):663-9. PubMed ID: 25065668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
